jRCT2080220801未知2 期
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertension
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Double-blind
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Aged 20 years and over at the time of consent
- •(2) Able to be hospitalized at the start and the end of study treatment; however, subjects may be treated on both an inpatient and outpatient basis at the time of consent
- •(3) Class I to III according to the World Health Organization (WHO) Pulmonary Hypertension Functional Classification at the time of consent
排除标准
- •(1) Use of catecholamines and/or PDE3 inhibitors for the treatment of cardiac failure at the time of consent
- •(2) Serious cardiac disorder not caused by pulmonary arterial hypertension, such as angina pectoris, myocardial infarction and myocarditis
- •(3) Previous participation in this study
研究者
相似试验
未知
2 期
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertensionJPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO
已完成
3 期
Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugsAcute ischemic stroke (excluding cardioembolic stroke)JPRN-UMIN000000758Asahi Kasei Pharma Corporation770
进行中（未招募）
不适用
A Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian CancerRecurrent high grade serous ovarian cancer.MedDRA version: 13.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015082-31-GBAbbott GmbH & Co. KG150
进行中（未招募）
不适用
A Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian CancerEUCTR2009-015082-31-HUAbbott GmbH & Co. KG150
已完成
1 期
Study of a marker of angiogenic response to combination therapy with pazopanib, and weekly paclitaxel in platinum resistant ovarian cancerGynaecological cancer, ovarian cancerMalignant neoplasm of ovaryCancerISRCTN38286161Imperial College London (UK)17